Survival and morbidity following stereotactic radiotherapy of hepatocellular carcinoma: a ten-year, single institution experience

References

• NORDCAN - Kræftstatistik for de nordiske lande. [cited 2020 Oct 20]. Available from: www.dep.iarc.fr/NORDCAN/DK
   Google Scholar
• Kliniske retningslinjer for udredning og behandling af HCC. [cited 2020 Oct 20]. Available from: http://www.gicancer.dk/kliniskeretningslinjerHCC.docx
   Google Scholar
• Rekommandationer for udførelse af stereotaktisk strålebehandling af tumorer i leveren. [cited 2020 Oct 20]. Available from: http://www.gicancer.dk/Retningslinier_DLGCG/Radioterapiudvalg.pdf
   Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–442.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005;15(4):279–283.
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5):1237–1248.
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Normolle S, Lawrence TS, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23(34):8739–8747.
   PubMed Web of Science ®Google Scholar
• MendezRomero A, Wunderink W, Levendag PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol. 2006;45:831–837.
   PubMed Web of Science ®Google Scholar
• Tse RV, Hawkins M, Dawson LA, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26(4):657–664.
   PubMed Web of Science ®Google Scholar
• Cárdenes HR, Price TR, Johnstone PA, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12(3):218–225.
   PubMed Web of Science ®Google Scholar
• Kang JK, Kim MS, Kim YH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118(21):5424–5431.
   PubMed Web of Science ®Google Scholar
• Price TR, Perkins SM, Cardenes HR, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2012;118(12):3191–3198.
   PubMed Web of Science ®Google Scholar
• Bujold A, Massey CA, Dawson LA, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–1639.
   PubMed Web of Science ®Google Scholar
• Sanuki N, Takeda A, Kunieda E, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol. 2014;53(3):399–404.
   PubMed Web of Science ®Google Scholar
• Su TS, Liang P, Liang JN, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol. 2016;113:181–187.
   PubMed Web of Science ®Google Scholar
• Takeda A, Sanuki N, Kunieda E, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122(13):2041–2049.
   PubMed Web of Science ®Google Scholar
• Nabavizedeh N, Waller JG, Hung AY, et al. Safety and efficacy of accelerated hypofractionation and stereotactic body radiation therapy for hepatocellular carcinoma patients with varying degrees of hepatic impairment. Int J Radiat Oncol Biol Phys. 2018;100:577–585.
   PubMed Web of Science ®Google Scholar
• Jeong Y, Jung J, Yoon SM, et al. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer. 2018;18(1):416.
   PubMedGoogle Scholar
• Huang WY, Jen YM, Chang YW, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;84(2):355–361.
   PubMed Web of Science ®Google Scholar
• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. [cited 2020 Oct 20]. Available from: www.easl.eu
   Google Scholar
• Worm ES, Høyer M, Poulsen PR, et al. Three-dimensional, time-resolved, intrafraction motion monitoring throughout stereotactic liver radiation therapy on a conventional linear accelerator. Int J Radiat Oncol Biol Phys. 2013;86(1):190–197.
   PubMed Web of Science ®Google Scholar
• Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 2015;114(2):155–160.
   PubMed Web of Science ®Google Scholar
• Worm ES, Bertholet J, Fledelius W, et al. Fiducial marker guided stereotactic liver radiotherapy: is a time delay between marker implantation and planning CT needed? Radiother Oncol. 2016;121(1):75–78.
   PubMed Web of Science ®Google Scholar
• Worm ES, Høyer M, Larsen LP, et al. A prospective cohort study of gated stereotactic liver radiation therapy using continuous internal electromagnetic motion monitoring. Int J Radiat Oncol Biol Phys. 2018;101(2):366–375.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, MacKenzie CR, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Gerum S, Heinz C, Roeder F, et al. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting. Strahlenther Onkol. 2020;196(4):334–348.
   PubMed Web of Science ®Google Scholar
• Gkika E, Schultheiss M, Brunner TB, et al. Excellent local control and tolerance profile after stereotactic body Radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol. 2017;12:116.
   PubMed Web of Science ®Google Scholar
• Baumann BC, Wei J, Ben-Josef E, et al. Stereotactic body radiation therapy (SABR) for hepatocellular carcinoma. High rates of local control with low toxicity. Am J Clin Oncol. 2018;11(41):1118–1124.
   Google Scholar
• Andersen KJ, Grønbaek H, Villadsen GE, et al. Chemoembolization of intermediate stage hepatocellular carcinomas: results from a Nordic tertiary liver cancer center. Indian J Gastroenterol. 2014;33(4):322–329.
   PubMedGoogle Scholar
• Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: a mini-review. World J Gastrointest Oncol. 2019;11(5):367–376.
   PubMed Web of Science ®Google Scholar
• Dobrzycka M, Spychalski P, Rostkowska O, et al. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol. 2019;58(12):1706–1713.
   PubMed Web of Science ®Google Scholar
• Su TS, Liang P, Deng X, et al. Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;98:639–646.
   PubMed Web of Science ®Google Scholar
• Wahl DR, Stenmark MH, Feng M, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–459.
   PubMed Web of Science ®Google Scholar
• Sapir E, Tao Y, Feng M, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(1):122–130.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Sugahara S, Tokuuye K, et al. Proton beam therapy for hepatocellulary carcinoma: the university of Tsukuba experience. Cancer. 2009;115(23):5499–5506.
   PubMed Web of Science ®Google Scholar
• Sanford NN, Pursley J, Hong TS, et al. Protons vs photons for unresectable hepetocellular carcinoma: liver decompensation and overall survival proton radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2019;105(1):64–72.
   PubMed Web of Science ®Google Scholar
• Chiba T, Tokuuye K, Akine Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11(10):3799–3805.
   PubMed Web of Science ®Google Scholar
• Beaton L, Dunne EM, Ma R, et al. Stereotactic body radiotherapy for large unresectable hepatocellular carcinomas – a single institution phase II study. Clin Oncol. 2020;32(7):423–432.
   Web of Science ®Google Scholar
• Villadsen GE, Simonsen K, Ott P, et al. Effects of implementation of a national fast track clinical pathway for hepatocellular carcinoma in western Denmark. JGLD. 2019;28(1):83–88.
   PubMed Web of Science ®Google Scholar